Preliminary note on the effect of denzimol in partial epilepsy.
The antiepileptic activity of the imidazole derivative denzimol has been evaluated in 10 patients with poorly controlled partial epilepsy by adding on the drug to the current therapy, in an open preliminary trial. A sustained drop in seizure frequency greater than 50% occurred in 5 patients. Although denzimol increased blood concentrations of carbamazepine, correlation analysis indicated that the improvement was more likely due to intrinsic properties of denzimol. No severe side effects were reported, although several patients experienced nausea and vomiting, which caused 2 patients to drop out.
Benassi
E
E
Clinica Neurologica dell'Università di Genova, Centro per la Diagnosi e la Terapia dell'Epilessia.
Cocito
L
L
Maffini
M
M
Bo
G P
GP
Loeb
C
C
D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004828:Epilepsies, Partial / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012640:Seizures / Q000188:drug therapy*
D000927:Anticonvulsants; D007093:Imidazoles; C031307:denzimol